Physician Assistant Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Anna Pruitt

Sports Medicine Winder, GA Physician Assistant

NPI 1578085395 CMS profile 3083457

299 N Broad St, Winder, GA 30680

Open in the dashboard

General payments

$6,044

327 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Pruitt of Winder, GA is reported in the CMS Open Payments database as having received $6,044 across 327 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,063 134
2024 General $1,841 80
2023 General $1,278 59
2022 General $368 26
2021 General $451 25
2020 General $42 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Pruitt
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Anna Pruitt were reported at $2,063. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Anna Pruitt Sports Medicine median Middle half National median
2019 $0 $1,176 $199–$4,249 $163
2020 $42 $708 $96–$2,890 $114
2021 $451 $1,213 $152–$3,994 $132
2022 $368 $1,230 $159–$3,998 $149
2023 $1,278 $584 $146–$2,836 $160
2024 $1,841 $628 $163–$3,168 $164
2025 $2,063 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. UCB, Inc. $664 30 payments
  2. Harmony Biosciences LLC $423 19 payments
  3. EMD Serono, Inc. $382 20 payments
  4. TG Therapeutics, Inc. $361 4 payments
  5. Teva Pharmaceuticals USA, Inc. $353 21 payments
  6. AbbVie, Inc. $328 36 payments
  7. Lundbeck LLC $285 11 payments
  8. Alexion Pharmaceuticals, Inc. $275 14 payments
  9. Pfizer Inc. $273 35 payments
  10. Eisai Inc. $257 13 payments
  11. Other $2,442 124 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $5,888 325 payments
  2. Education $156 2 payments
Products named General payments · program years 2020–2025
  1. BRIUMVI $361 4 payments
  2. Briviact $275 11 payments
  3. QULIPTA $262 30 payments
  4. NURTEC ODT $255 33 payments
  5. UBRELVY $237 30 payments
  6. Leqembi $233 12 payments
  7. ZAVZPRET $221 30 payments
  8. VYEPTI $208 7 payments
  9. WAKIX $203 9 payments
  10. Austedo XR $179 15 payments
  11. Other $3,799 197 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

3,267

Median for Orthopaedic Surgery: 30

Drug cost

$743,112

Median for Orthopaedic Surgery: $176

Branded share of claims

33.1%

Median for Orthopaedic Surgery: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 25 $319,197
Ubrelvy Ubrogepant Brand 71 $72,344
Qulipta Atogepant Brand 48 $71,656
Nurtec Odt Rimegepant Sulfate Brand 47 $70,613
Emgality Pen Galcanezumab-Gnlm Brand 84 $67,404
Copaxone Glatiramer Acetate Brand 11 $61,495
Memantine Hcl Generic 412 $9,015
Carbidopa-Levodopa Carbidopa/Levodopa Brand 310 $8,078
Rivastigmine Rivastigmine Tartrate Brand 94 $6,228
Gabapentin Generic 433 $6,094

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,233 Part D prescribers listed as Orthopaedic Surgery; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
  • Harmony Biosciences LLC $203
$203 — —
Leqembi
  • Eisai Inc. $140
$140 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $134
$134 — —
Briviact
  • UCB, Inc. $101
$101 — —
Rystiggo
  • UCB, Inc. $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

327 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record